Ted Wang - Ekso Bionics Director
| EKSO Stock | USD 1.25 0.03 2.34% |
Director
Dr. Ted Wang, Ph.D., serves as Director of the Company. Dr. Wang has served as the Chief Investment Officer of Puissance Capital Management LP, of which he was a founder, since January 2015. Prior to that, Dr. Wang was a Partner of Goldman, Sachs Co., which he joined in 1996 and with which he served in many leadership positions, mostly recently as CoHead of U.S. Equities Trading and Global CoHead of One Delta Trading and a member of the Goldman Sachs Risk Committee. Prior to joining Goldman, Dr. Wang cofounded Xeotron Corporationration, a company specializing in DNA biochips in Texas since 2017.
| Age | 50 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | 101 Glacier Point, San Rafael, CA, United States, 94901 |
| Phone | 510 984 1761 |
| Web | https://www.eksobionics.com |
Ekso Bionics Management Efficiency
The company has return on total asset (ROA) of (0.2706) % which means that it has lost $0.2706 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7989) %, meaning that it created substantial loss on money invested by shareholders. Ekso Bionics' management efficiency ratios could be used to measure how well Ekso Bionics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of April 2024, Return On Tangible Assets is likely to drop to -0.68. In addition to that, Return On Capital Employed is likely to drop to -0.76. At this time, Ekso Bionics' Total Current Assets are very stable compared to the past year. As of the 28th of April 2024, Non Currrent Assets Other is likely to grow to about 504.2 K, while Total Assets are likely to drop about 26 M.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Leonard Schiller | Milestone Scientific | 73 | |
| Giovannella Deiure | LeMaitre Vascular | 49 | |
| Sebastian Burckhardt | Straumann Holding AG | 64 | |
| Moshe Pinto | Nephros | N/A | |
| Edward Zelnick | Milestone Scientific | 68 | |
| Carsten Hellmann | Coloplast A | 53 | |
| Thomas Gwydir | Nephros | N/A | |
| Christopher Sansone | InfuSystems Holdings | N/A | |
| Raymond Cabillot | Pro Dex | 54 | |
| Daniel Mumford | LeMaitre Vascular | 42 | |
| Roger Stebbing | ATRION | 76 | |
| Alfred Vargas | Nephros | N/A | |
| Regula Wallimann | Straumann Holding AG | 51 | |
| Thomas Barfod | Coloplast A | 53 | |
| John Roush | LeMaitre Vascular | 53 | |
| Barbara Payne | Utah Medical Products | 70 | |
| Arthur Amron | Nephros | 61 | |
| Sven Bjorklund | Coloplast A | 59 | |
| Joergen TangJensen | Coloplast A | 61 | |
| Birgitte Nielsen | Coloplast A | 54 | |
| David Hovda | Pro Dex | 55 | |
Management Performance
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.27 |
Ekso Bionics Holdings Leadership Team
Elected by the shareholders, the Ekso Bionics' board of directors comprises two types of representatives: Ekso Bionics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ekso. The board's role is to monitor Ekso Bionics' management team and ensure that shareholders' interests are well served. Ekso Bionics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ekso Bionics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Maximilian SchederBieschin, CFO | ||
| Howard Palefksy, Director | ||
| Dan Boren, Independent Director | ||
| Steven Sherman, Chairman of the Board | ||
| Stanley Stern, Independent Director | ||
| Rachael Anderson, Global Growth | ||
| Russ Angold, Co-Founder and President of Ekso Labs Division | ||
| Jason Jones, Chief Officer | ||
| John Glenn, CFO, Secretary | ||
| Bill Shaw, Chief Commercial Officer | ||
| Foon Chwee, President APAC | ||
| Scott Davis, Chief Officer | ||
| Jerome Wong, Corporate Controller | ||
| Stephan Aderhold, Senior EMEA | ||
| Theodore Wang, Director | ||
| Amy Wendell, Director | ||
| Jack Peurach, Independent Director | ||
| Russdon Angold, CTO | ||
| Thomas Looby, Pres and Chief Commercial Officer | ||
| Ann Cookson, Human Director | ||
| Marilyn Hamilton, Independent Director | ||
| Matthias Stief, Managing Director | ||
| Charles Li, Director | ||
| Thomas Schreck, Director | ||
| Nathan Harding, Co-Founder, CEO and Director | ||
| Ted Wang, Director | ||
| Anthony Pratt, Vice Sales |
Ekso Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ekso Bionics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.8 | ||||
| Return On Asset | -0.27 | ||||
| Profit Margin | (0.83) % | ||||
| Operating Margin | (0.71) % | ||||
| Current Valuation | 21.45 M | ||||
| Shares Outstanding | 17.9 M | ||||
| Shares Owned By Insiders | 13.00 % | ||||
| Shares Owned By Institutions | 7.60 % | ||||
| Number Of Shares Shorted | 190.33 K | ||||
| Price To Earning | (0.67) X |
Pair Trading with Ekso Bionics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ekso Bionics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ekso Bionics will appreciate offsetting losses from the drop in the long position's value.Moving together with Ekso Stock
| 0.8 | GH | Guardant Health Financial Report 14th of May 2024 | PairCorr |
| 0.61 | IDXX | IDEXX Laboratories Financial Report 7th of May 2024 | PairCorr |
Moving against Ekso Stock
| 0.81 | HCWB | HCW Biologics | PairCorr |
| 0.74 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.68 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.6 | MTD | Mettler Toledo Inter Financial Report 2nd of May 2024 | PairCorr |
| 0.58 | TMO | Thermo Fisher Scientific | PairCorr |
The ability to find closely correlated positions to Ekso Bionics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ekso Bionics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ekso Bionics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ekso Bionics Holdings to buy it.
The correlation of Ekso Bionics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ekso Bionics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ekso Bionics Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ekso Bionics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Ekso Bionics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for Ekso Stock analysis
When running Ekso Bionics' price analysis, check to measure Ekso Bionics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ekso Bionics is operating at the current time. Most of Ekso Bionics' value examination focuses on studying past and present price action to predict the probability of Ekso Bionics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ekso Bionics' price. Additionally, you may evaluate how the addition of Ekso Bionics to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |
Is Ekso Bionics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ekso Bionics. If investors know Ekso will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ekso Bionics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.10) | Revenue Per Share 1.318 | Quarterly Revenue Growth 0.365 | Return On Assets (0.27) | Return On Equity (0.80) |
The market value of Ekso Bionics Holdings is measured differently than its book value, which is the value of Ekso that is recorded on the company's balance sheet. Investors also form their own opinion of Ekso Bionics' value that differs from its market value or its book value, called intrinsic value, which is Ekso Bionics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ekso Bionics' market value can be influenced by many factors that don't directly affect Ekso Bionics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ekso Bionics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ekso Bionics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ekso Bionics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.